EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim By Ogkologos - September 18, 2025 389 0 Facebook Twitter Google+ Pinterest WhatsApp Vivlipeg is highly similar to the reference product Neulasta, which was authorised in the EU in 2002 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR ΚΑΡΚΙΝΟΣ ΟΥΡΟΔΟΧΟΥ ΚΥΣΤΕΩΣ March 8, 2019 How Alcohol Increases Your Cancer Risk and What to Know About... August 29, 2023 Living With Metastatic Breast Cancer: How I Reinvented Myself October 30, 2020 Ahead of a Key Meeting of EU Health Ministers, ESMO Calls... June 14, 2026 Load more HOT NEWS Expressive Writing, What is It? Embedding research integrity at the core of our science Approval Expanded for Venetoclax in Chronic Lymphocytic Leukemia Dad With Cancer Escorts His Autistic Son To School, With The...
